Presentation is loading. Please wait.

Presentation is loading. Please wait.

Preoperative Exercise Vo2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238  Gregory M. Loewen, DO, Dorothy.

Published byJeremy Weaver Modified over 5 years ago

Similar presentations

Presentation on theme: "Preoperative Exercise Vo2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238  Gregory M. Loewen, DO, Dorothy."— Presentation transcript:

1 Preoperative Exercise Vo2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238  Gregory M. Loewen, DO, Dorothy Watson, MS, Leslie Kohman, MD, James E. Herndon, PhD, Hani Shennib, MD, Kemp Kernstine, MD, PhD, Jemi Olak, MD, M Jeffery Mador, MD, David Harpole, MD, David Sugarbaker, MD, Mark Green, MD  Journal of Thoracic Oncology  Volume 2, Issue 7, Pages (July 2007) DOI: /JTO.0b013e318074bba7 Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Distribution of Cancer and Leukemia Group B (CALGB) patients in the CALGB 9238 algorithm. FEV1-ppo, predicted postoperative forced expiratory volume in 1 second; Vo2, oxygen consumption. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318074bba7) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Distribution of Cancer and Leukemia Group B Patients applying the functional operability (FO) algorithm. *VO2 corrected for body mass in kilograms (ml/min/kg). FEV1, forced expiratory volume in 1 second; ppo, predicted postoperative; DLCO, single breath diffusion capacity; VO2, oxygen consumption; VO2 max, maximal oxygen consumption. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318074bba7) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Median survival times were 15.9 months and 36.0 months for nonsurgical and surgical patients, respectively (p = ), shown in the Kaplan-Meier survival curve. CALGB, Cancer and Leukemia Group B. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318074bba7) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Preoperative Exercise Vo2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238  Gregory M. Loewen, DO, Dorothy."

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304  Martin J. Edelman, MD, Lydia.

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB   Martin J. Edelman, MD, Lydia.
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
The Utility of Exercise Testing in Patients with Lung Cancer

The Utility of Exercise Testing in Patients with Lung Cancer
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D
Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer? 

Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer? 
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Lung cancer staging and treatment in multidisciplinary trials: cancer and leukemia group B cooperative group approach1  Mark J Krasna, MD, Carolyn E Reed,

Lung cancer staging and treatment in multidisciplinary trials: cancer and leukemia group B cooperative group approach1  Mark J Krasna, MD, Carolyn E Reed,
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Utility of Exercise Testing in Patients with Lung Cancer

The Utility of Exercise Testing in Patients with Lung Cancer
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection  Charlotte Billiet, MD, Stéphanie.

Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection  Charlotte Billiet, MD, Stéphanie.
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months  Arturo Navarro-Martin, MD, Samantha Aso, MD, Jon Cacicedo,

Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months  Arturo Navarro-Martin, MD, Samantha Aso, MD, Jon Cacicedo,

Similar presentations

Ads by Google